Associated Papers
Pharmacogenetics Approach for Personalized Tacrolimus Dosing in Heart Transplantation: A Case Report and Literature Review.
Nikpalj N et al.
Genes, 2025
Rapid clearance of tacrolimus blood concentration triggered by variant pharmacogenes.
Šimičević L et al.
Journal of Clinical Pharmacy and Therapeutics, 2022
Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.
Božina N et al.
Arhiv Za Higijenu Rada I Toksikologiju, 2021
ABCB1, ABCG2, ABCC1, ABCC2, and ABCC3 drug transporter polymorphisms and their impact on drug bioavailability: what is our current understanding?
Bruckmueller H et al.
Expert Opinion on Drug Metabolism & Toxicology, 2021
The association of transporter ABCC2 (MRP2) genetic variation and drug-induced hyperbilirubinemia.
Huang YS et al.
Journal of the Chinese Medical Association : Jcma, 2021
ABC transporter superfamily. An updated overview, relevance in cancer multidrug resistance and perspectives with personalized medicine.
Juan-Carlos PM et al.
Molecular Biology Reports, 2021
CYP3A5 and UGT1A9 Polymorphisms Influence Immunosuppressive Therapy in Pediatric Kidney Transplant Recipients.
Krall P et al.
Frontiers in Pharmacology, 2021
A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China.
Wu L et al.
Orphanet Journal of Rare Diseases, 2020
ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects.
Cao K et al.
European Journal of Clinical Pharmacology, 2020
Pharmacogenetics of Membrane Transporters of Tacrolimus in Solid Organ Transplantation.
Tron C et al.
Clinical Pharmacokinetics, 2019
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
Deferasirox associated with liver failure and death in a sickle cell anemia patient homozygous for the -1774delG polymorphism in the Abcc2 gene.
Braga CCB et al.
Clinical Case Reports, 2017
Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.
Calcagno A et al.
Clinical Pharmacokinetics, 2017
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E et al.
International Journal of Molecular Sciences, 2017
Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.
Matthaei J et al.
Genome Medicine, 2016
Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review.
Chen S et al.
Drug Metabolism Reviews, 2016
Clinical implementation of pharmacogenetics.
García-González X et al.
Drug Metabolism and Personalized Therapy, 2016
How polymorphisms of the cytochrome P450 genes affect ibuprofen and diclofenac metabolism and toxicity.
Krasniqi V et al.
Arhiv Za Higijenu Rada I Toksikologiju, 2016
Clinically relevant genetic variants of drug-metabolizing enzyme and transporter genes detected in Thai children and adolescents with autism spectrum disorder.
Medhasi S et al.
Neuropsychiatric Disease and Treatment, 2016
Effect of MRP2 and MRP3 Polymorphisms on Anastrozole Glucuronidation and MRP2 and MRP3 Gene Expression in Normal Liver Samples.
Edavana VK et al.
International Journal of Cancer Research and Molecular Mechanisms, 2015
The recessive model of MRP2 G1249A polymorphism decrease the risk of drug-resistant in Asian Epilepsy: a systematic review and meta-analysis.
Wang Y et al.
Epilepsy Research, 2015
Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.
Nishijima T et al.
Plos One, 2015
Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.
Meyer zu Schwabedissen HE et al.
Bmc Research Notes, 2014
Using Drosophila melanogaster to identify chemotherapy toxicity genes.
King EG et al.
Genetics, 2014
Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK et al.
Pharmacogenetics and Genomics, 2014
Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohort.
Ulzurrun E et al.
Plos One, 2014
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?
Baietto L et al.
Current Drug Metabolism, 2014
Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy.
Becker ML et al.
The Pharmacogenomics Journal, 2013
Linkage disequilibrium between polymorphisms of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex partial seizures on treatment with carbamazepine mono-therapy at the Kuala Lumpur Hospital.
Subenthiran S et al.
Plos One, 2013
Pharmacogenetic study of deferasirox, an iron chelating agent.
Lee JW et al.
Plos One, 2013
UGT1A9, UGT2B7, and MRP2 genotypes can predict mycophenolic acid pharmacokinetic variability in pediatric kidney transplant recipients.
Fukuda T et al.
Therapeutic Drug Monitoring, 2012
ABCC2 Haplotype is Associated With Antituberculosis Drug-Induced Maculopapular Eruption.
Kim SH et al.
Allergy, Asthma & Immunology Research, 2012
Associations between ABCC2 polymorphisms and cisplatin disposition and efficacy.
Sprowl JA et al.
Clinical Pharmacology and Therapeutics, 2012
Human pregnane X receptor genotype of the donor but not of the recipient is a risk factor for delayed graft function after renal transplantation.
Hauser IA et al.
Clinical Pharmacology and Therapeutics, 2012
Influence of MRP2 on MPA pharmacokinetics in renal transplant recipients-results of the Pharmacogenomic Substudy within the Symphony Study.
Lloberas N et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association, 2011
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
Effect of ABCC2 (MRP2) transport function on erythromycin metabolism.
Franke RM et al.
Clinical Pharmacology and Therapeutics, 2011
Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function.
Laechelt S et al.
The Pharmacogenomics Journal, 2011
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.
Man M et al.
Journal of Clinical Pharmacology, 2010
Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.
Afsar NA et al.
Basic & Clinical Pharmacology & Toxicology, 2010
A nonsynonymous variation in MRP2/ABCC2 is associated with neurological adverse drug reactions of carbamazepine in patients with epilepsy.
Kim WJ et al.
Pharmacogenetics and Genomics, 2010
The 5'-untranslated region of multidrug resistance associated protein 2 (MRP2; ABCC2) regulates downstream open reading frame expression through translational regulation.
Zhang Y et al.
Molecular Pharmacology, 2010
UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.
van Schaik RH et al.
Clinical Pharmacology and Therapeutics, 2009
Telmisartan pharmacokinetics in Japanese renal transplant recipients.
Miura M et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2009
Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia.
Davidsen ML et al.
Journal of Pediatric Hematology/oncology, 2008
Pharmacogenomics: a tool for improving cancer chemotherapy.
Monzó M et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008
Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol.
Haenisch S et al.
Pharmacogenetics and Genomics, 2008
High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations.
Rau T et al.
Clinical Pharmacology and Therapeutics, 2006
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
Anderson PL et al.
Journal of Acquired Immune Deficiency Syndromes (1999), 2006